Compare · ARGX vs BCRX
ARGX vs BCRX
Side-by-side comparison of argenx SE (ARGX) and BioCryst Pharmaceuticals Inc. (BCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BCRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 25.6x BCRX ($2.14B).
- Over the past year, ARGX is up 51.2% and BCRX is down 24.0% - ARGX leads by 75.3 points.
- BCRX has been more active in the news (7 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 24 for BCRX).
- Company
- argenx SE
- BioCryst Pharmaceuticals Inc.
- Price
- $882.63-1.03%
- $8.44+0.36%
- Market cap
- $54.76B
- $2.14B
- 1M return
- +12.11%
- -5.17%
- 1Y return
- +51.24%
- -24.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 1994
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 24
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest BCRX
- Director Milne Jill C. was granted 1,262 shares, increasing direct ownership by 8% to 16,644 units (SEC Form 4)
- Director Stonehouse Jon P was granted 631 shares, increasing direct ownership by 0.05% to 1,324,481 units (SEC Form 4)
- Director Mckee Amy E was granted 631 shares, increasing direct ownership by 2% to 31,883 units (SEC Form 4)
- Director Milano Vincent was granted 1,122 shares, increasing direct ownership by 1% to 93,189 units (SEC Form 4)
- Director Frank Steven was granted 1,262 shares, increasing direct ownership by 7% to 20,165 units (SEC Form 4)
- BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
- Director Mckee Amy E sold $100,285 worth of shares (11,180 units at $8.97), decreasing direct ownership by 26% to 31,252 units (SEC Form 4)
- Chief Legal Officer Barnes Alane P exercised 62,500 shares at a strike of $5.04 and sold $596,250 worth of shares (62,500 units at $9.54) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by BioCryst Pharmaceuticals Inc.
- BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026